APNIMED INC
APMDNASDAQ🏆 #2519 by market capUS Equity
$19.24▼ $0.21 (−1.08%)
Latest quoteTrack APMD
Get earnings, price moves & breaking news on Telegram
24h▼ 1.1%
7d▲ 3.1%
14d▲ 5.5%
30d▼ 19.7%
ytd—
1y—
🏦Market Cap
$801M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $18.08 – $19.62
- 52-Week Range
- $16.00 – $35.29
- Volume (shares)
- 17,978
- Avg Volume (shares)
- —
- Shares Outstanding
- 41.6M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
APNIMED INC
APMDFinancial Trends
Financial history unavailable.
StockOtter · stockotter.spaceAbout APNIMED INC
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚡Momentum★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
10 analysts
Strong Buy3
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.